|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017636,
umls-concept:C0030705,
umls-concept:C0076080,
umls-concept:C0205390,
umls-concept:C0332283,
umls-concept:C0521115,
umls-concept:C0677908,
umls-concept:C0971473,
umls-concept:C1518321,
umls-concept:C1522449,
umls-concept:C2603343
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2010-5-28
|
|
pubmed:abstractText |
Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:ClementPaul M JPM,
pubmed-author:DietrichPierre-YvesPY,
pubmed-author:DiserensAnnie-ClaireAC,
pubmed-author:GoldbrunnerRolandR,
pubmed-author:GrabenbauerGerhard GGG,
pubmed-author:HegiMonika EME,
pubmed-author:HermissonMirjamM,
pubmed-author:HickingChristineC,
pubmed-author:KruegerStefanS,
pubmed-author:NeynsBartB,
pubmed-author:OchsenbeinAdrian FAF,
pubmed-author:PicaAlessiaA,
pubmed-author:PicardMartinM,
pubmed-author:PietschTorstenT,
pubmed-author:SchlegelUweU,
pubmed-author:SimonMatthiasM,
pubmed-author:StuppRogerR,
pubmed-author:TonnJoerg-ChristianJC,
pubmed-author:WellerMichaelM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2712-8
|
|
pubmed:dateRevised |
2010-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:20439646-Adult,
pubmed-meshheading:20439646-Aged,
pubmed-meshheading:20439646-Antineoplastic Agents, Alkylating,
pubmed-meshheading:20439646-Biopsy, Needle,
pubmed-meshheading:20439646-Brain Neoplasms,
pubmed-meshheading:20439646-Combined Modality Therapy,
pubmed-meshheading:20439646-Confidence Intervals,
pubmed-meshheading:20439646-Dacarbazine,
pubmed-meshheading:20439646-Disease-Free Survival,
pubmed-meshheading:20439646-Dose-Response Relationship, Drug,
pubmed-meshheading:20439646-Drug Administration Schedule,
pubmed-meshheading:20439646-Female,
pubmed-meshheading:20439646-Follow-Up Studies,
pubmed-meshheading:20439646-Glioblastoma,
pubmed-meshheading:20439646-Humans,
pubmed-meshheading:20439646-Immunohistochemistry,
pubmed-meshheading:20439646-Infusions, Intravenous,
pubmed-meshheading:20439646-Kaplan-Meier Estimate,
pubmed-meshheading:20439646-Male,
pubmed-meshheading:20439646-Maximum Tolerated Dose,
pubmed-meshheading:20439646-Middle Aged,
pubmed-meshheading:20439646-Neoplasm Recurrence, Local,
pubmed-meshheading:20439646-Neoplasm Staging,
pubmed-meshheading:20439646-Neurosurgical Procedures,
pubmed-meshheading:20439646-Probability,
pubmed-meshheading:20439646-Radiotherapy, Adjuvant,
pubmed-meshheading:20439646-Radiotherapy, Conformal,
pubmed-meshheading:20439646-Risk Assessment,
pubmed-meshheading:20439646-Snake Venoms,
pubmed-meshheading:20439646-Survival Analysis,
pubmed-meshheading:20439646-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
|
|
pubmed:affiliation |
Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland. roger.stupp@chuv.ch
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
